Tuberculosis Clinical Trial
Official title:
A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults
Background: Non-Steroid Anti-Inflammatory Drugs (NSAIDs) reduce pain and inflammation by
inhibiting cyclooxygenase, an enzyme in the pathway for formation of prostaglandins and
thromboxane. Prior studies have proven the role of ibuprofen (an NSAID) in modulating lung
injury and decreasing pulmonary damage in cystic fibrosis. While there has been an intense
effort by the scientific community to define the best treatment strategies for tuberculosis
immune reconstitution inflammatory syndrome (TB-IRIS), to our knowledge there is no
available study evaluating preventive strategies using anti-inflammatory agents for TB-IRIS,
a highly morbid complication in HIV-infected TB patients initiating antiretroviral therapy
(ART).
Design and Methods: We propose to conduct a single center double-blind placebo-controlled
randomized trial to investigate the efficacy of daily self-administered Meloxicam (a NSAID)
versus placebo for prevention of Tuberculosis associated Immune Reconstitution Inflammatory
Syndrome (TB-IRIS). A total of 150 HIV-infected adults who are treated for Tuberculosis for
at least 2 weeks and about to initiate HIV treatment at Brewelskloof Hospital, Worcester,
and Tygerberg Teaching Hospital, Cape Town, will be randomized to one of the following
treatments: Meloxicam 7.5 mg tablet once-a-day, the experimental arm, versus Placebo tablet
once-a-day, the control arm, for 8 weeks. All patients will be followed up for 12 months.
Primary efficacy outcome: The decrease of the incidence of paradoxical TB IRIS by at least
20%; Primary safety outcome: The proportion of patients who temporarily or permanently
discontinue Meloxicam due to any adverse event (e.g. dyspepsia or gastro-intestinal upset).
Secondary outcomes are: 1) the proportion of patients in each arm with the following
indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort >III,
presence of local or disseminated suppuration/abscess of any site, unscheduled clinic
visits, hospitalizations, missed more than a day at work, etc; 2) The incidence of other
types of IRIS (e.g. Kaposi Sarcoma or cryptococcal meningitis).
This study will provide important and novel data on the feasibility and efficacy of using a
cheap, widely available NSAID used in both developed and developing countries, as a
preventive intervention for TB-IRIS that could be quickly put into practice if proven to be
effective
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |